Bayer Focusing On Early CKD Testing In Kerendia US Launch

Less Than 50% Of Doctors Use UACR For Earlier Diagnosis

The company, which set a list price of $19 per day, sees awareness of diagnosing chronic kidney disease in type 2 diabetes patients as the top challenge for newly approved finerenone in the US.

Human kidneys medicine treatment concept
Kerendia (finerenone) is a kidney disease-specific treatment for CKD associated with diabetes • Source: Alamy

Bayer AG brought in a new sales team specifically to promote Kerendia (finerenone) in the US for chronic kidney disease (CKD) in patients with type 2 diabetes, and those representatives will hit the ground running later this month. The US Food and Drug Administration approved the non-steroidal mineralocorticoid receptor antagonist on 9 July and the company is working to manufacture enough of the once-daily pills to distribute the product to retail pharmacies within the next two weeks.

Kerendia is indicated to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, kidney failure, cardiovascular death, non-fatal...

Welcome to Scrip

Create an account to read this article

More from New Products

S&E In Brief: Launch Trends And Regulatory Updates Among SMID Biopharmas

 

Ultragenyx updated investors on interactions with the US FDA on gene therapy, while new drug launches were themes for Ionis and Organon in Q2 reporting.

Pipeline Watch: Ten Approvals And Fourteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Biogen Edges Closer To Growth On Strong Q2

 

Sales of Leqembi, Zurzuvae and Skyclarys contributed to Biogen’s sales and earnings guidance raise, positioning the company closer to potential growth.

PTC To Challenge BioMarin In PKU With Oral Sephience

 
• By 

PTC plans to compete with BioMarin’s two phenylketonuria drugs with efficacy data showing strong reduction of phenylalanine and ability for patients to liberalize their diets.

More from Scrip

Direct-To-Consumer And Lower Prices Key To Novo Nordisk’s Wegovy Fightback

 

The company’s incoming CEO Mike Doustdar has promised greater agility, competitiveness and execution, but investors are yet to be convinced.

Can Bayer’s Pharmaceuticals Division Help It Weather A Perfect Storm?

 
• By 

Bayer continues to keep faith in its pharmaceuticals business despite a plethora of problems for the wider group with job cuts, continued debt concerns and ongoing glyphosate litigation claims.

BridgeBio Becomes The Victim Of Its Own Success As Attruby Gathers Steam

 
• By 

Shares of the Palo Alta, CA-based firm fell as Attruby sales missed elevated investor expectations in the second full quarter since its launch.